$EVLO on NASDAQ
October 17, 2023
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
August 14, 2023
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
July 12, 2023
Evelo Biosciences Closes $25.5 Million Private Placement
July 10, 2023
Evelo Biosciences Announces $25.5 Million Private Placement
June 29, 2023
Evelo Biosciences Announces Reverse Stock Split Effective
April 26, 2023
Evelo Biosciences Provides Clinical Updates
March 16, 2023
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 09, 2023
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
March 01, 2023
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
February 27, 2023
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
February 01, 2023
Evelo Biosciences Provides Clinical and Business Updates
January 11, 2023
Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update
December 16, 2022
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt
November 15, 2022
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
November 14, 2022
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
November 08, 2022
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
September 07, 2022
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
September 01, 2022
Evelo Biosciences Announces Grant of Inducement Award
September 01, 2022
Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference
August 11, 2022
Evelo Biosciences Announces Succession Plan
August 11, 2022
Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights
August 05, 2022
Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
July 18, 2022
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
May 25, 2022
Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock
May 12, 2022
Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
April 21, 2022
Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors
April 14, 2022
Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs
April 06, 2022
Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors
March 26, 2022
Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting
March 24, 2022
Evelo Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
March 17, 2022
Evelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
March 07, 2022
Evelo Biosciences to Host KOL Discussion on Treatment Advances for All Stages of Psoriasis and Potential of SINTAX Medicines
March 02, 2022
Evelo Biosciences to Participate in Cowen 42nd Annual Health Care Conference
February 28, 2022
Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis
February 17, 2022
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis
February 07, 2022
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial
January 17, 2022
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases
January 04, 2022
Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts
December 14, 2021
Evelo Biosciences Added to Nasdaq Biotechnology Index
November 09, 2021
Evelo Biosciences to Present at 2021 Jefferies London Healthcare Conference
October 28, 2021
Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights
October 21, 2021
Evelo Biosciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
October 13, 2021
Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
September 27, 2021
Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease
September 20, 2021
Evelo Biosciences to Present at 2021 Cantor Global Healthcare Conference
September 09, 2021
Evelo Biosciences Announces Issuance of U.S. Patent for Pharmaceutical Compositions of Single Strains of Naturally Occurring Bacteria as Medicines
September 07, 2021
Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors
July 29, 2021
Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights
July 22, 2021
Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
July 14, 2021
Evelo Biosciences Announces Grant of Inducement Award
- No Recent Filings Found.
